Vision Research

Usher Syndrome Society Commits Another $500,000 for New Round of Usher Syndrome Research Grants

Retrieved on: 
Thursday, July 20, 2023
Retina, Letter, Usher syndrome, University, Vision Research, Hearing loss, Boston Children's Hospital, USH, Research, Paratriathlon, Karger Publishers, Massachusetts Eye and Ear, Hearing, Weill Cornell Medicine, Hospital, University of Oregon, Ear, Pharmaceutical industry

About the Usher Syndrome SocietyThe USH Society is a non--profit created because of an urgent need to save the sight and hearing of those living with Usher syndrome. Realizing that the two most important ways to accelerate research are educating the public and raising research funds, the USH Society began using photojournalism, film, and educational events to bring Usher syndrome to the forefront of rare diseases. The Usher Syndrome Society is a registered 501(c)3. Visit www.UsherSyndromeSociety.org for more information.

Key Points: 
  • Funded projects will help drive collaborative ear-­‐and-­‐eye Usher syndrome research focused on the discovery pipeline including identification of therapeutic strategies and development of novel therapeutic agents.
  • NEEDHAM, Mass., July 20, 2023 /PRNewswire/ -- The Usher Syndrome Society (USH Society), a non-­‐ profit that uses storytelling through the arts, educational events, and collaboration to raise public awareness and funds for research to find treatments and a cure for Usher syndrome (USH) announces a request for applications for Usher syndrome research grants.
  • The "Usher Syndrome Society Translational Research Grants" are intended to support translational research on Usher syndrome in either Preclinical Research and/or Mechanism-­‐based Therapeutic Development.
  • The USH Society is committed to supporting Usher syndrome research at labs with promising work and specific funding needs that accelerate Usher syndrome research towards treatments and a cure.

Dr. SriniVas R. Sadda Named 2023-2024 ARVO President Elect

Retrieved on: 
Tuesday, June 27, 2023
Srinivas, Retina, ARVO, University, Vision Research, Eye, Research, Doctor of Philosophy, Bangladesh Technical Education Board, Imaging, Trustee, Annual general meeting, Artificial intelligence, Association for Research in Vision and Ophthalmology, UCLA, NIH, New Orleans, Doheny Eye Institute, David Geffen School of Medicine at UCLA, Management, Ophthalmology, MD, Medicine

PASADENA, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research institutions, announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 Annual Meeting in New Orleans, La.

Key Points: 
  • PASADENA, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Doheny Eye Institute , one of the nation’s leading vision research institutions, announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 Annual Meeting in New Orleans, La.
  • Dr. Sadda has been a member of ARVO for a number of years, and served on the Board of Trustees for the past three years.
  • “We are eager to see Dr. Sadda step into his new role of ARVO President Elect, as he has already proven to be an integral member of our board over the last few years,” said J.
  • “Being selected to serve as President Elect, and ultimately President in another year, is a tremendous honor and career highlight.

Iowa family builds farm-based craft brewery to help deliver a cure for blindness

Retrieved on: 
Thursday, May 4, 2023
Retina, Autumn, IVR, Partnership, University, Vision Research, Beer, IA, Multimedia, Paratriathlon, Retinitis pigmentosa, IPA, Blind, Hage, Love, B cell, Family, Disease, Online shopping

INWOOD, Iowa, May 4, 2023 /PRNewswire/ -- In 2020 a family in northwest Iowa began making their own craft beer as a hobby during the pandemic.

Key Points: 
  • INWOOD, Iowa, May 4, 2023 /PRNewswire/ -- In 2020 a family in northwest Iowa began making their own craft beer as a hobby during the pandemic.
  • Those efforts took a serious turn when the owners of the Blind Butcher Brewing Company found a cause worth fighting for – a mission to cure blindness.
  • "We are very excited to have the Hage family's BREWS for BLiNDNESS partnership in our efforts..." says Dr. Stone.
  • This IPA will retail throughout Iowa and in their taproom with the proceeds benefiting BREWS for BLiNDNESS to support the IVR.

Multi-Platinum Selling Artist Chris Janson to Perform at BrightFocus Foundation Charity Gala on June 14

Retrieved on: 
Monday, April 24, 2023
Glaucoma, University, Nashville Songwriters Association International, BrightFocus Foundation, Vision Research, Macular degeneration, Fix a Drink, Cone Health Women's Hospital, Boat, NBC News, University of Pennsylvania, Research, OTD, Grand Ole Opry, Good Vibes, Doctor of Philosophy, Science, Harvard Medical School, Vision, MSNBC, Buy Me a Boat, Alzheimer's disease, Glen Campbell, Johns Hopkins University, Perelman School of Medicine at the University of Pennsylvania, Reading, American Indians, Washington University School of Medicine, Janson, Artificial intelligence, Multi, Hospital, Rolling Stone, Gala, National Museum of the American Indian, Management, Nursing, Smithsonian Institution, MSCI, Brigham, MD

Janson has collaborated with such iconic country artists as Hank Williams Jr., Tim McGraw, Eric Church, Blake Shelton, and Travis Tritt.

Key Points: 
  • Janson has collaborated with such iconic country artists as Hank Williams Jr., Tim McGraw, Eric Church, Blake Shelton, and Travis Tritt.
  • "We look forward to featuring Chris Janson and honoring today's leaders in Alzheimer's, glaucoma, and macular degeneration research at our 50th-anniversary event," said Stacy Haller, President and CEO, BrightFocus Foundation.
  • "Research is the only key to ending these devastating mind and sight diseases that affect more than 300 million people worldwide."
  • The Gala will take place at the Smithsonian's National Museum of the American Indian in Washington, D.C., and will highlight the impact of numerous scientific breakthroughs attributable to BrightFocus Foundation's 50 years of biomedical research funding.

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

Retrieved on: 
Tuesday, March 14, 2023
DFN, Pesticide, Vision Research, CNS, Ophthalmology, MHW, Tablet, Growth, Ministry, Medicinal plants, Health

FREMONT, Calif., March 14, 2023 /PRNewswire/ -- ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the Company based in Fremont, California, received an approval of Maitake Mushroom Dietary Supplement Tablet from Taiwan Ministry of Health and Welfare (MHW) on February 6, 2023.

Key Points: 
  • FREMONT, Calif., March 14, 2023 /PRNewswire/ -- ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the Company based in Fremont, California, received an approval of Maitake Mushroom Dietary Supplement Tablet from Taiwan Ministry of Health and Welfare (MHW) on February 6, 2023.
  • Taiwan Ministry of Health & Welfare approves Maitake Mushroom Dietary Supplement Tablets from ABVC BioPharma subsidiary.
  • Shipment of the first bulk lot of Maitake Mushroom Tablets to Define Biotech is in progress for the commercial launch in Taiwan.
  • "We are pleased to receive the registrational approval of our Maitake Mushroom Tablets "DFN" from Taiwan MHW," said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.

Vision Research Supplies Embedded Phantom High-Speed Camera for Use With FDA-Cleared Sepsis Test

Retrieved on: 
Monday, January 30, 2023
Manufacturing, Photography, Audio, Video, Other Science, Pharmaceutical, Research, Other Technology, Medical Devices, Hardware, Science, Technology, Clinical Trials, FDA, General Health, Biotechnology, Health, Other Manufacturing, Engineering, Chemicals, Plastics, Food and Drug Administration, VEO, Multimedia, CMOS, Blood, Flow cytometry, Phantom, Vision Research, Camera, Medical imaging

Vision Research, a leading manufacturer of digital high-speed imaging systems, has for the first time supplied an embedded Phantom high-speed camera for use within a medical device with U.S. Food and Drug Administration (FDA) 501(k) clearance.

Key Points: 
  • Vision Research, a leading manufacturer of digital high-speed imaging systems, has for the first time supplied an embedded Phantom high-speed camera for use within a medical device with U.S. Food and Drug Administration (FDA) 501(k) clearance.
  • View the full release here: https://www.businesswire.com/news/home/20230130005509/en/
    The Phantom VEO 710 high-speed camera is critical to Cytovale®’s groundbreaking IntelliSep® test.
  • It is also a well-established camera used in a variety of industries and applications, with the proven reliability necessary for long-term success.
  • “Phantom VEO high-speed cameras provide valuable insights into many biological and biomedical events that are otherwise too fast to be seen,” says Toni Lucatorto, Product Manager, Vision Research.

Kubota Vision Announces the Results of Clinical Study in Children Using Wearable Myopia Control Device based on Kubota Glass Technology

Retrieved on: 
Tuesday, September 6, 2022
Optical, Health, Clinical Trials, Medical Devices, Nanotechnology, CEO, Research, View, Ophthalmology, Doctor of Philosophy, OCT, Kubota, Incidence, Publishing, Vision Research, MD, Company, Risk, Â, Trial of the century, Patient, Visual impairment, Pharmaceutical industry, Myopia

Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the results from a clinical study in children using a wearable myopia control device based on Kubota Glass technology.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the results from a clinical study in children using a wearable myopia control device based on Kubota Glass technology.
  • We will continue accumulating evidence for Kubota Glass technology as a safe, effective and easy approach to control myopia.
  • Kubota Pharmaceutical groups pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Kubota Vision Announces Publication in Scientific Reports; Effects of Using Projected Peripheral Myopic Defocus

Retrieved on: 
Thursday, July 14, 2022
Medical Devices, Health, Clinical Trials, Research, Science, Optical, Stargardt disease, Myopia, Retina, Diabetic retinopathy, Vision Research, Engineering, MVA, OCT, Glass, Psychology, View, Patient, CEO, CooperVision, Adult, MD, Food, Scientific Reports, Population, Medicine, Springer Nature, FDA, Research, Food and Drug Administration, Doctor of Philosophy, PLOS, University, Pharmaceutical industry, Medical device

Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal Scientific Reports, entitled Biometric and refractive changes following the monocular application of peripheral myopic defocus using a novel augmented-reality optical system in adults.
  • This was a 4-month prospective clinical study conducted at MVA to investigate the effects of using projected peripheral myopic defocus in a benchtop optical system.
  • The primary objective of the study was to assess the central axial length and cycloplegic refractive changes using a novel optical system and myopic defocus stimulus design.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Retrieved on: 
Thursday, January 20, 2022
U.S. Securities and Exchange Commission, Targeting (international health), Research, Bausch & Lomb, Forward-looking statement, Canadian Securities Administrators, News, Bausch Health, Vaccine, LinkedIn, R, University, Eye, IPO, National Alliance, COVID-19, Gastroenterology, Drug, CMO, Verteporfin, NYSE, AbbVie, CEO, Medicine, Employee Benefits Security Administration, Instagram, INSEAD, Global health, History, BHC, Research and development, Facebook, Industry, Vision Research, Phrase, Head, Shijiazhuang Pharma Group, Risk, Lens (anatomy), Twitter, Failure, Cairo University, Physician, Acquisition, Medical device, Fine chemical, Pharmaceutical industry, Bausch, QC, Allergan, Ophthalmology, Dermatology

LAVAL, QC, Jan. 20, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022.

Key Points: 
  • LAVAL, QC, Jan. 20, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022.
  • "I am excited that Dr. Hashad will lead the R&D organization and serve as CMO at Bausch + Lomb.
  • "Dr. Hashad will play a critical role in helping to shape the future of R&D at Bausch + Lomb."
  • Effective Jan. 31, 2022, Dr. Hashad will join Bausch + Lomb.

New Phantom S991 Machine Vision High-Speed Camera Provides Extreme Throughput With New Fiber Technology

Retrieved on: 
Tuesday, January 11, 2022
Other Manufacturing, Technology, Packaging, Engineering, Other Technology, Photography, Manufacturing, Audio, Video, Hardware, Consumer Electronics, EOS, Research, Business development, Ametek, ISO, Science, MPX, CXP, Phantom, View, Vision Research, Monochrome, Multimedia, Color, Engineering, CoaXPress, Machine vision, Acquisition, Television, Camera

Vision Research, a leading manufacturer of digital high-speed imaging systems, brings extreme throughput to machine vision applications with the introduction of the Phantom S991 Machine Vision camera.

Key Points: 
  • Vision Research, a leading manufacturer of digital high-speed imaging systems, brings extreme throughput to machine vision applications with the introduction of the Phantom S991 Machine Vision camera.
  • View the full release here: https://www.businesswire.com/news/home/20220111005224/en/
    Vision Research brings extreme throughput to machine vision applications with the introduction of the Phantom S991 Machine Vision camera (Photo: Business Wire)
    The Phantom S991 offers users very high quality, detailed images.
  • Additionally, the Phantom S991 is designed to achieve very high frame rates and throughput by using CoaXPress-over-Fiber (CXPoF), the latest innovative machine vision protocol.
  • The Phantom S991 with CXP-over-Fiber technology brings significant benefits to machine vision applications, explains Dan Hafen, Director of Business Development for Machine Vision at Vision Research.